Andexanet alfael esperado antídoto de los anticoagulantes directos inhibidores del factor Xa

  1. María García-Uría Santos
Zeitschrift:
MPG Journal

ISSN: 2171-9020

Datum der Publikation: 2019

Titel der Ausgabe: Candidemia, ¿es necesaria la valoración rutinaria del fondo de ojo?

Ausgabe: 2

Nummer: 44

Art: Artikel

DIALNET GOOGLE SCHOLAR lock_openOpen Access editor

Andere Publikationen in: MPG Journal

Zusammenfassung

Acute major bleeding episodes associated with factor Xa inhibitors (rivaroxaban, apixaban, edoxaban and enoxaparin) may be difficult to treat due to the lack of a specific reversal agent. Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors that markedly reduced anti–factor Xa activity with good hemostatic efficacy.

Bibliographische Referenzen

  • Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808.
  • Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016; 375: 1131- 41.
  • Ghadimi K, Dombrowski KE, Levy JH, Welsby IJ. Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. Expert Rev Hematol 2016; 9: 11522.
  • Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19: 446-51.
  • Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015; 373: 2413-24.
Fuente de los datos: Dialnet